EPEIUS BIOTECHNOLOGIES RECEIVES ACCELERATED APPROVAL FOR REXIN-G IN THE PHILIPPINES

Epeius Biotechnologies announced the Bureau of Food and Drugs (BFAD), the Philippine drug regulatory body, has granted Epeius Biotechnologies accelerated approval for the company's lead clinical product, Rexin-G for the treatment of all solid tumors. This approval closely follows the recent granting of an Expanded Access Program by BFAD to Epeius for Rexin-G, which extended Rexin-G clinical applications to patients with solid tumors, including but not limited to pancreatic cancer. Drug Newswire (http://www.drugnewswire.com/4685/)